Sangamo Therapeutics, Inc.
NASDAQ:SGMO
2.71 (USD) • At close November 12, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Sangamo Therapeutics, Inc. |
Symbool | SGMO |
Munteenheid | USD |
Prijs | 2.71 |
Beurswaarde | 564,278,910 |
Dividendpercentage | 0% |
52-weken bereik | 0.3 - 3.18 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. |
Website | https://www.sangamo.com |
An error occurred while fetching data.
Over Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)